ArticleCancer2021

Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.

Abhishek Maiti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.